Genomtec S.A. (GMT) - Net Assets
Based on the latest financial reports, Genomtec S.A. (GMT) has net assets worth zł7.02 Million PLN (≈ $1.93 Million USD) as of March 2026. Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (zł13.03 Million ≈ $3.59 Million USD) and total liabilities (zł6.01 Million ≈ $1.65 Million USD). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off. Check GMT goodwill-adjusted equity ratio to evaluate the tangible quality of the company's equity base.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | zł7.02 Million |
| % of Total Assets | 53.87% |
| Annual Growth Rate | 47.01% |
| 5-Year Change | 0.37% |
| 10-Year Change | N/A |
| Growth Volatility | 291.64 |
Genomtec S.A. - Net Assets Trend (2019–2024)
This chart illustrates how Genomtec S.A.'s net assets have evolved over time, based on quarterly financial data. See how many days can Genomtec S.A. fund operations to measure how many days the company can operate on defensive assets alone.
Annual Net Assets for Genomtec S.A. (2019–2024)
The table below shows the annual net assets of Genomtec S.A. from 2019 to 2024. For live valuation and market cap data, see Genomtec S.A. stock valuation.
| Year | Net Assets | Change |
|---|---|---|
| 2024-12-31 | zł7.60 Million ≈ $2.09 Million |
-8.46% |
| 2023-12-31 | zł8.30 Million ≈ $2.28 Million |
+68.47% |
| 2022-12-31 | zł4.93 Million ≈ $1.36 Million |
+567.75% |
| 2021-12-31 | zł738.00K ≈ $203.11K |
-90.25% |
| 2020-12-31 | zł7.57 Million ≈ $2.08 Million |
+584.74% |
| 2019-12-31 | zł1.11 Million ≈ $304.34K |
-- |
Equity Component Analysis
This analysis shows how different components contribute to Genomtec S.A.'s total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 4859857400.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2024)
| Component | Amount | Percentage |
|---|---|---|
| Common Stock | zł1.33 Million | 17.53% |
| Other Comprehensive Income | zł14.20 Million | 186.89% |
| Other Components | zł43.37 Million | 570.66% |
| Total Equity | zł7.60 Million | 100.00% |
Genomtec S.A. Competitors by Market Cap
The table below lists competitors of Genomtec S.A. ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Vietnam Sun Corp
VN:VNS
|
$20.65 Million |
|
Pantheon International PLC
LSE:PIN
|
$20.67 Million |
|
Modular Medical Inc
NASDAQ:MODD
|
$20.67 Million |
|
Big Yellow Group PLC
LSE:BYG
|
$20.68 Million |
|
ERSU Meyve ve Gida Sanayi AS
IS:ERSU
|
$20.64 Million |
|
Agat Ejendomme A/S
CO:AGAT
|
$20.64 Million |
|
PIL ITALICA LIFESTYLE LIMITED
NSE:PILITA
|
$20.64 Million |
|
Pure Hydrogen Corporation Ltd
AU:PH2
|
$20.63 Million |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Genomtec S.A.'s equity between the two most recent reporting periods.
Equity Growth Insights
- From 2023 to 2024, total equity changed from 8,302,000 to 7,600,000, a change of -702,000 (-8.5%).
- Net loss of 11,208,000 reduced equity.
- New share issuances of 10,506,000 increased equity.
Equity Change Factors (2023 to 2024)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | zł-11.21 Million | -147.47% |
| Share Issuances | zł10.51 Million | +138.24% |
| Total Change | zł- | -8.46% |
Book Value vs Market Value Analysis
This analysis compares Genomtec S.A.'s book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 8.74x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 36.74x to 8.74x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2019-12-31 | zł0.14 | zł4.98 | x |
| 2020-12-31 | zł0.93 | zł4.98 | x |
| 2021-12-31 | zł0.09 | zł4.98 | x |
| 2022-12-31 | zł0.52 | zł4.98 | x |
| 2023-12-31 | zł0.68 | zł4.98 | x |
| 2024-12-31 | zł0.57 | zł4.98 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Genomtec S.A. utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): -147.47%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: -1120800.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 2.24x
- Recent ROE (-147.47%) is above the historical average (-293.24%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2019 | -130.83% | -947.38% | 0.05x | 2.63x | zł-1.56 Million |
| 2020 | -144.47% | -54695.00% | 0.00x | 1.24x | zł-11.70 Million |
| 2021 | -984.09% | -3248.86% | 0.05x | 5.83x | zł-7.19 Million |
| 2022 | -244.03% | -29820.00% | 0.00x | 2.41x | zł-12.42 Million |
| 2023 | -108.56% | -901300.00% | 0.00x | 1.92x | zł-9.84 Million |
| 2024 | -147.47% | -1120800.00% | 0.00x | 2.24x | zł-11.97 Million |
Industry Comparison
This section compares Genomtec S.A.'s net assets metrics with peer companies in the Medical Devices industry.
Industry Context
- Industry: Medical Devices
- Average net assets among peers: $35,209,226
- Average return on equity (ROE) among peers: -9.77%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Genomtec S.A. (GMT) | zł7.02 Million | -130.83% | 0.86x | $20.65 Million |
| Adiuvo Investment SA (ADV) | $-44.73 Million | 0.00% | 0.00x | $1.86 Million |
| Braster S.A. (BRA) | $29.02 Million | -68.18% | 0.88x | $4.69 Million |
| Medinice S.A (ICE) | $40.58 Million | -7.10% | 0.21x | $212.39 Million |
| Medicalg (MDG) | $80.93 Million | 13.44% | 0.03x | $73.96 Million |
| Synektik S.A. (SNT) | $70.25 Million | 13.00% | 0.78x | $695.75 Million |
About Genomtec S.A.
Genomtec S.A. researches and develops a mobile point of care genetic testing platform for the clinical diagnostics market in Poland. The company's flagship project is the Genomtec ID, a diagnostic platform that offer mobile genetic diagnosis to patients through streamlined nucleic acid amplification technology (SNAAT) to detect viruses, bacteria, and fungi, as well as genetic mutations by analysi… Read more